Nuvaxovid

Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M, the active ingredient in Nuvaxovid, is a vaccine presented as a dose for intramuscular use. It protects against COVID-19 in adults and older adults. GNH USA supplies Nuvaxovid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Nuvaxovid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nuvaxovid is a recombinant protein COVID‑19 vaccine that stimulates immunity against SARS‑CoV‑2.

- Prevention of COVID‑19: induces protective antibodies and T‑cell responses in adults. - Booster vaccination: enhances immunity in individuals previously vaccinated with other COVID‑19 vaccines. - Protection for high‑risk populations: provides additional protection for older adults and immunocompromised patients. - Travel‑related vaccination: helps meet entry requirements for international travel. - Outbreak response inclusion: can be deployed in public‑health campaign to curb community transmission.

Common Side Effects: - Injection site pain - Fatigue - Headache - Muscle soreness - Fever - Nausea

Serious or Rare Side Effects: - Anaphylaxis - Guillain‑Barré syndrome - Myocarditis - Thrombosis with thrombocytopenia syndrome (TTS) - Severe allergic reactions beyond anaphylaxis - Acute neurologic events such as seiz seizures

Nuvaxovid should be administered by a qualified ‑ healthcare professional in a clinical setting.

- Contraindication: Severe severe severe  t  t -  t  ewline -  ewline  ewline -  ewline \n t  ewline  ewline  ewline  ewline  ewline - ullet  ewline - ullet    ewline - Store  t  ewline - ullet ullet  ewline - ullet  ewline -   ewline

The  g   ef  ewline  ewline

   ewline